Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesWound CarePriority Health skin substitutes Coverage Update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy 91560

    SKIN SUBSTITUTES & SOFT TISSUE GRAFTS

    Customize your policy alerts

    Sign up for priority health Policy 91560 alerts

    Get alerted when Policy 91560 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria, limitations, and coding requirements for skin substitutes and soft tissue graft products used by Priority Health members; applies to providers submitting claims for these products.

    Policy Summary
    Payerpriority health
    PolicySKIN SUBSTITUTES & SOFT TISSUE GRAFTS
    Policy CodePolicy 91560
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization when required and document a ≥4-week trial of optimized standard wound care with wound measurements and perfusion assessment before applying a skin substitute.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Multipleindication groups
    ≥4 weeksstandard care trial
    ≥50%wound area reduction threshold
    12 weeksmax episode duration
    ≤10max applications

    Coverage Criteria and Medical Necessity

    General Medical Necessity Requirements

    Covered when ALL of the following general requirements are met

    General requirements: Documentation of wound characteristics and a treatment plan are present prior to application
    Regulatory status: Product is FDA-regulated (e.g., PMA, 510(k), HDE, or HCT/P) and is used consistent with its regulatory status
    Allergy/safety: Member has no documented hypersensitivity or allergy to any components of the skin substitute
    Indication-specific criteria: Applicable indication-specific medical necessity criteria in this policy are satisfied
    Policy Summary
    Payerpriority health
    PolicySKIN SUBSTITUTES & SOFT TISSUE GRAFTS
    Policy CodePolicy 91560
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization when required and document a ≥4-week trial of optimized standard wound care with wound measurements and perfusion assessment before applying a skin substitute.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCoding, HCPCS/CPT/ICD-10 and Regulatory IdentifiersPrior Authorization, Documentation, Billing and Denial RiskBackground and RationaleDefinitions and Terms

    Breast Reconstruction

    Breast reconstruction — Covered when ONE or more criteria are met (AND general requirements)

    Breast reconstruction adjunctive criteria: Inadequate pectoralis major muscle or chest wall soft-tissue to provide appropriate coverage/support for a tissue expander or implant
    Breast reconstruction adjunctive criteria: Skin flaps are thin, poorly perfused, or otherwise compromised and at increased risk for wound-related complications
    Breast reconstruction adjunctive criteria: Disruption of the inframammary and/or lateral mammary fold during mastectomy requiring surgical re-establishment to support reconstructive outcomes
    ADM use limitation: ADMs considered medically necessary only as adjunctive soft-tissue support/reinforcement in implant-based reconstruction (not standalone); use requires individualized decision-making and documented informed consent regarding off-label status and risks

    Burns

    Burn-related indications — Covered when general burn prerequisites plus indication-specific criteria are met

    General burn prerequisites: Assessment documented including burn depth, TBSA, anatomic location, and functional risk areas; wound bed appropriate and infection controlled (or product used after adequate debridement/excision and infection control); plan of care documents why standard therapy alone is insufficient; product used consistent with FDA-regulated intent
    Indication-specific options: Temporary epidermal/biosynthetic coverage for clean superficial/partial-thickness burns when autografting is not indicated
    Indication-specific options: Partial-thickness burns requiring advanced coverage to support epithelialization (ReCell® eligible for adults where indicated)
    Indication-specific options: Temporary coverage following surgical excision of full-thickness or deep partial-thickness burns prior to definitive autografting in staged management
    Indication-specific options: Mid-dermal or indeterminate-depth burns expected to heal without autograft but needing temporary biologic/biosynthetic coverage to protect the wound bed
    Indication-specific options: Extensive deep dermal or full-thickness burns where dermal/epidermal replacement is indicated (e.g., burns involving ≥30% TBSA) or when autografting is limited/insufficient
    Indication-specific options: Donor-site coverage after split-thickness grafting to protect fresh, clean, non-infected donor sites and support epithelialization
    Indication-specific options: Reconstructive burn surgery for functional impairment (scar/contracture) when autograft is limited by insufficient donor skin or patient factors

    Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU)

    Chronic lower-extremity ulcers (DFU & VLU) — Covered when ALL of the following are met

    Ulcer characteristics: Partial- or full-thickness ulcer that does not involve exposed bone, tendon, muscle, or joint capsule
    Failed standard care: Ulcer has failed to demonstrate meaningful healing (≥50% area reduction) after ≥4 weeks of documented adherence to standard wound/ulcer care including regular debridement when indicated, appropriate dressings/cleansing, infection assessment/management, and etiology-specific foundational therapy (offloading for DFU; sustained compression for VLU)
    Perfusion assessment: Adequate arterial perfusion documented by one method: palpable pedal pulses or Doppler signals; or ABI ≥0.70 and ≤1.30; or when ABI unreliable (>1.30), toe pressure ≥30 mmHg or TBI not consistent with severe ischemia
    Adjunctive and safety requirements: Skin substitute is used as an adjunct to standard care (not a replacement); product is FDA-regulated and used consistent with regulatory status; no uncontrolled infection and no hypersensitivity/allergy to product components
    DFU-specific additional requirements: For DFU, member has type 1 or type 2 diabetes; HbA1c assessed within the last 90 days and diabetes management being optimized (HbA1c <12% required unless documented reason to proceed); absence of DFU-specific contraindications (no active Charcot deformity or major structural foot abnormality, no chronic uncontrolled infection, and no known or suspected malignancy at the ulcer site)

    General medical necessity criteria (chronic lower-extremity ulcers)

    Covered when ALL of the following are met for chronic lower-extremity ulcers (DFU or VLU):

    General inclusion: Partial or full-thickness ulcer without exposed bone, tendon, muscle, or joint capsule
    Prior standard care trial: Ulcer failed to demonstrate meaningful healing (>=50% area reduction) after >=4 weeks of documented adherence to standard wound/ulcer care including regular debridement, appropriate dressings/cleansing, and infection assessment/management>=50% area reduction after >=4 weeks
    Etiology-specific foundational therapy: Documented and continued: offloading for DFU; sustained compression therapy and edema management for VLU
    Perfusion assessment: Adequate arterial perfusion documented by one of: palpable pedal pulses or Doppler signals; ABI >=0.70 and <=1.30; or when ABI unreliable (ABI>1.30), toe pressure >=30 mmHg or TBI not consistent with severe ischemiaABI >=0.70 and <=1.30; toe pressure >=30 mmHg
    Adjunctive use and regulatory conformity: Skin substitute used as an adjunct to standard care and product used consistent with FDA/regulatory status with wound characteristics documented prior to application
    Contraindications: No uncontrolled infection in the wound; no hypersensitivity/allergy to product components

    DFU-specific medical necessity criteria

    DFU-specific Covered when ALL of the following apply (in addition to general criteria C.1):

    Diabetes diagnosis: Member has type 1 or type 2 diabetes
    Glycemic assessment: Hemoglobin A1c assessed within the last 90 days and diabetes management being optimized; HbA1c <12% required unless clinical documentation supports why delay is necessaryHbA1c <12% within 90 days
    DFU-specific contraindications: No active Charcot deformity or major structural abnormality of the affected foot; no chronic infection not adequately treated/controlled; no known or suspected malignancy of the ulcer site

    VLU-specific medical necessity criteria

    VLU-specific Covered when ALL of the following apply (in addition to general criteria C.1):

    Etiology: Ulcer attributable to chronic (≥3 months) venous insufficiency/venous stasis>=3 months
    Compression therapy: Sustained compression therapy is documented as part of standard venous ulcer care and will be continued throughout treatment
    Do not replace foundational therapy: Skin substitutes are not a replacement for compression therapy and should not be used prior to an adequate trial of standard venous ulcer care

    Product-specific utilization limits

    Product-specific utilization rules (apply when medical necessity met):

    AlloPatch Pliable (Q4128): Full-thickness DFU >6 weeks; initial up to 5 applications; additional to a maximum of 8 applications within a 12-week treatment episode per ulcer may be considered when evidence of healing is present; additional applications beyond 12 weeks are not medically necessary>6 weeks; initial<=5; max<=8 in 12 weeks
    Dermagraft® (Q4431): Full-thickness DFU >6 weeks; initial up to 5 applications; additional up to 8 applications within 12 weeks may be considered when evidence of healing is present; additional applications beyond 12 weeks are not medically necessary>6 weeks; initial<=5; max<=8 in 12 weeks
    OrCel™ (C9399): Medically necessary only for surgical wounds/donor sites after surgical release of mitten‑hand deformities in RDEB per FDA HDE; not for routine DEB wounds or prophylactic use
    Combined human/animal, tri-layer, other products: Many products have defined initial application limits (often 1) and caps (commonly 4–5, or up to 8–10) within a 12‑week episode depending on product; additional applications beyond 12 weeks are not medically necessary

    General medical necessity criteria

    Covered when ALL of the following are met (general approach reflected in document):

    General coverage criteria: 1) Wound has received optimized standard care (debridement when indicated, infection assessment/management, moisture balance, and etiology‑specific measures such as offloading for DFUs or compression for VLUs); 2) For DFUs, objective vascular assessment shows adequate perfusion or acceptable toe pressure/TBI when ABI is unreliable; 3) The wound demonstrates inadequate progress (e.g., fails to achieve approximately ≥50% area reduction after ≥4 weeks) or other clinical rationale for adjunctive advanced therapy; 4) Product selection is indication‑appropriate and supported by product‑specific evidence where available

    Evidence-linked product considerations

    Product-specific supportive evidence examples (informational; not an exhaustive approval list):

    AlloPatch Pliable evidence: Prospective RCT (n=80) showed weekly HR‑ADM plus SOC produced higher complete closure rates at 6 and 12 weeks versus SOC alone and shorter mean time to healing; supports adjunctive use in selected chronic DFUs when criteria met

    Zelen et al., 2018

    EpiCord evidence: Multicenter RCT demonstrated higher 12‑week closure rates versus standardized care in chronic nonhealing DFUs after a run‑in period, supporting adjunctive use when wounds fail to progress with optimized conservative management

    Tettelbach et al., 2019

    AmnioBand/dHACA evidence: RCTs report higher 12‑week closure rates and faster mean healing when added weekly to SOC in DFUs (e.g., 85% vs 33% in an RCT), supporting selected adjunctive use

    Burn-specific criteria

    Burn care coverage context (adjunctive/conditional use):

    Burns - when substitutes are appropriate: Skin substitutes may be used for temporary coverage, dermal replacement, or to support healing when autologous grafting is not immediately feasible or donor sites are limited (e.g., burns involving ≥30% TBSA, medically unstable patients, or critical anatomic areas); use should follow standard burn management principles and be documented in specialized burn care settingsTBSA >=30% may indicate advanced product or CEA HDE use

    Breast reconstruction guidance

    Breast reconstruction (ADM) stance:

    ADM in implant-based breast reconstruction: ADMs and soft‑tissue scaffolds are commonly used adjuncts, but high‑quality comparative evidence does not consistently show improved long‑term clinical or patient‑reported outcomes versus non‑ADM approaches; use requires individualized decision‑making, patient counseling about off‑label use and risks, and documentation of informed consent

    General adjunctive coverage criteria

    Adjunctive use supported when ALL of the following are met:

    Adjunctive therapy prerequisites: Wound is evaluated and managed with optimized standard care specific to etiology (debridement, infection assessment/management, moisture balance, offloading for DFUs or sustained compression for VLUs) and is failing to progress despite adequate trial; product selection is indication‑appropriate and supported by product‑specific evidence; documentation includes serial wound measurements and rationale for adjunctive therapy

    Product-specific evidence (informational)

    Product-specific evidence (informational) — examples cited in the policy:

    AlloPatch Pliable (HR-ADM): RCT (n=80) showed higher closure at 6 and 12 weeks versus SOC when used weekly as adjunct in selected chronic DFUs with offloading and SOC; supports effectiveness in appropriately selected patients

    Zelen et al., 2018

    EpiCord/dHUC: Multicenter RCT (2:1 randomization) demonstrated higher 12‑week closure rates versus standardized care in chronic nonhealing DFUs after a run‑in; supports adjunctive use when wounds fail to progress with optimized conservative management

    Tettelbach et al., 2019

    AmnioBand/dHACA: RCTs report higher 12‑week closure (e.g., 85% vs 33%) and faster mean healing when added weekly to SOC in DFUs

    DiDomenico et al., 2018

    Placental-derived and other CTPs in VLUs: Selected RCTs (Apligraf, OASIS, EpiFix, AmnioBand) show improved healing when used with compression in hard‑to‑heal VLUs; compression must be continued

    Regulatory listings (informational)

    Regulatory listings (informational) — FDA product identifiers and device associations are provided for reference and verification

    Regulatory references: Policy lists FDA PMA/510(k)/HCT/P identifiers and associated product names for skin substitutes and wound matrices; these listings are informational and do not by themselves establish medical necessity

    Regulatory identifiers (informational)

    Regulatory listings and product associations; no coverage decision criteria provided in these chunks.

    Regulatory listing: FDA identifiers (P/K numbers and HCT/P designations) are enumerated alongside named products and are available to support product verification in prior authorization or claims documentation

    Not Medically Necessary — general rule

    General policy stance for exclusions and medical necessity

    Not medically necessary general rule: Procedures, services, or products that do not meet the medical necessity criteria in this policy, including those that are excluded, investigational, or unproven (E/I/U), are considered not medically necessary and are not eligible for coverage
    Not separately payable/add-on: Items that are integral to another procedure or lack sufficient high-quality evidence demonstrating independent efficacy are designated not separately payable (add-on) and excluded from separate reimbursement

    Not Separately Payable / Add-on items

    Not Separately Payable / Add-on items

    Not separately payable: Specific products and HCPCS/Q-codes listed in the policy are designated not separately payable (add-on) and must be billed per the add-on/listed‑with‑primary guidance; consult the coding section for mapped codes

    Medical necessity review

    Medical necessity review — prior authorization and individual case review processes

    Prior authorization and review: When prior authorization is required by plan rules, providers must submit documentation demonstrating medical necessity; individual case review may allow coverage for investigational but promising treatments only with prior plan approval
    Decision authority: Determinations for experimental, investigational, or unproven treatments will be made by a Priority Health medical director or clinical pharmacist and exceptions are limited (e.g., terminal illness or severely disabling disease causing serious clinical deterioration)

    General medical necessity

    General medical necessity — coverage determinations and plan-level applicability

    Coverage logic: Coverage requires that the requested product, service, or procedure be medically necessary and consistent with the member's specific benefits and applicable plan documents; group/plan documents may supersede this policy where applicable

    Investigational/Unproven therapy exception criteria

    Investigational/Unproven therapy exception criteria — narrow, exceptional allowances

    Allowable exceptions: Individual consideration for investigational, unproven, or E/I/U treatments may be granted only if the condition is a terminal illness OR a chronic, life‑threatening, severely disabling disease causing serious clinical deterioration; prior plan approval and review by a Priority Health medical director or clinical pharmacist are required

    Acellular dermal matrices (ADMs) are recognized as adjunctive soft‑tissue support in implant‑based breast reconstruction and are not intended as standalone reconstructive materials. Use of ADMs as primary reconstructive materials, as load‑bearing structural components, or for purely cosmetic, prophylactic, or preference‑based enhancements does not meet medical necessity and is excluded. Routine, cosmetic‑only applications and investigational uses (including use under an IDE) are also explicitly not medically necessary.

    Skin substitutes and ADMs are considered experimental, investigational, or unproven when applied to superficial or partial‑thickness burns that are expected to heal with conventional wound management. Inclusion of a product on a listing or table does not itself establish medical necessity; substitutes meet medical necessity for burns only when used for dermal replacement, reinforcement, or temporary coverage consistent with a qualifying burn indication.

    The policy excludes prophylactic application (including application to closed or epithelialized ulcers) and use on ulcers that are infected, ischemic, necrotic, or gangrenous until those conditions are adequately treated. Skin substitutes should not be used in place of required foundational therapies (for example, revascularization for primarily ischemic wounds or sustained compression for VLUs) and multiple concurrent or sequential products for the same ulcer require documented clinical rationale to be considered.

    OrCel™ (reported in this policy mapping as C9399) is medically necessary only within its FDA‑approved humanitarian device indication — specifically, for wounds or donor sites created after surgical release of mitten‑hand deformities in RDEB. Use of OrCel™ outside that humanitarian indication is considered experimental/investigational/unproven and is excluded.

    There is no single FDA regulatory category labeled 'skin substitutes'; products in this clinical class enter the market through differing regulatory pathways (PMA, 510(k), HCT/P, etc.). Lack of FDA clearance/approval for a specific indication or use may affect coverage determinations and products must be used consistent with their regulatory status.

    Skin substitutes and CTPs are adjunctive treatments and should not replace foundational etiology‑specific care. For example, venous leg ulcers require sustained therapeutic compression as first‑line therapy; skin substitutes are considered only when compression and other standard venous care have been optimized and documented.

    Sections that list FDA identifiers, device names, and clearance dates provide regulatory reference only and do not by themselves state coverage exclusions or alter the medical necessity rules elsewhere in the policy.

    Similarly, regulatory listings elsewhere in the document enumerate product names and FDA identifiers but do not include explicit coverage determinations or not‑medically‑necessary declarations within those listing segments.

    Additional regulatory listing chunks present FDA product/clearance identifiers and product associations; these chunks provide informational regulatory mapping but do not state coverage exclusions or authorization rules.

    Regulatory identifiers (510(k)/PMA/HCT‑P numbers) and associated product names are included in this section for reference; the entries are informational and do not themselves specify medical necessity or exclusions.

    Additional regulatory product listings repeat FDA identifiers and product names. These entries serve as regulatory references and do not convey coverage decisions or explicit exclusions within the listing text.

    This segment lists further FDA 510(k)/PMA identifiers and product names (e.g., Kerecis entries, Matristem, Mirragen) as regulatory reference. No coverage rules or exclusions are specified within these regulatory product lists.

    The policy contains an extensive list of specific products and HCPCS/Q/A‑series codes that are designated as not separately payable or as add‑on items to be reported with a primary procedure rather than billed as standalone services. Many named products and A‑ or Q‑codes are explicitly mapped to this not‑separately‑payable/add‑on designation.

    A broad set of named skin substitute and soft‑tissue graft products in the exclusions section are mapped to Q‑codes and are listed as add‑on items or otherwise excluded from separate reimbursement. Injectable, flowable, or particulate formulations are specifically noted for some products and affect billing designation.

    The exclusions include an extensive enumeration of Q‑codes and HCPCS C‑codes (and many A‑series entries) that are designated as add‑on, not separately payable, or otherwise excluded from separate payment. Examples include numerous Q4xxx entries and the C9352–C9364 group of collagen/nerve/scaffold C‑codes.

    Treatments and products determined to be experimental, investigational, or unproven are generally excluded from coverage. Requests to consider such therapies require prior plan approval and review by a Priority Health medical director or clinical pharmacist; exceptions are limited (for example, terminal or severely deteriorating conditions) and require individual case review.

    Routine or cosmetic‑only uses, investigational applications, use under an IDE, or uses outside FDA‑regulated homologous intent are treated as not medically necessary regardless of whether a product appears elsewhere in the policy. The policy therefore excludes such uses from coverage.

    The policy limits repeated applications: more than one skin substitute application to the same wound on the same date is not medically necessary, and repeat or alternative full courses within 1 year after an unsuccessful prior course are not considered medically reasonable and necessary unless specific exception criteria are met. The policy also caps total applications per ulcer to a maximum over defined treatment episodes and sets a maximum episode duration (see product and limitations sections).

    The policy emphasizes that skin substitutes are intended as adjuncts to — not replacements for — optimized standard care. Use of skin substitutes as a first‑line or replacement therapy without evidence of an adequate trial and optimization of standard treatments is not supported by the policy.

    Skin substitutes should not be used as first‑line replacements for foundational etiology‑specific therapies. For VLUs this specifically means compression is foundational: substitutes are considered only after an adequate trial (commonly ≥4–6 weeks) of compression and standard wound care, and compression must be continued when adjunctive products are used.

    Regulatory listing sections include product and FDA identifier references but do not contain explicit 'not medically necessary' determinations; coverage decisions are defined elsewhere in the policy by clinical criteria and exclusions.

    Chunked regulatory listings (e.g., product names with PMA/510(k) identifiers and dates) are informational; these chunks do not declare products or indications as 'not medically necessary' and must be interpreted in the context of the policy's clinical criteria.

    The regulatory identifier listings found in other chunks likewise do not make explicit 'not medically necessary' statements; they provide FDA mapping that may assist prior authorization or claims validation but do not override the clinical criteria in the coverage sections.

    Additional regulatory listings (product names and K/P numbers) are informational only and do not include standalone coverage or exclusion language; medical necessity is determined by the clinical criteria sections of the policy.

    Regulatory product lists that repeat FDA identifiers and product names are present for reference. These chunks do not provide coverage rules or state exclusions; coverage determinations rely on satisfaction of the policy's clinical criteria.

    Examples of procedures or products that do not meet medical necessity criteria are provided in the exclusions section; the policy reiterates that items failing to meet the defined clinical criteria — including investigational or unproven treatments — are not eligible for coverage.

    The exclusions section lists specific example product codes noted in noncoverage statements (for example, connective tissue nonhuman/synthetic code C1763 is cited under not medically necessary examples) to illustrate the policy's approach to excluded uses.

    HCPCS C‑codes for collagen, nerve, and scaffold products (C9352–C9364 as listed) are designated Not separately payable in this policy — these items are considered integral to other services or lack evidence to support separate reimbursement.

    As a general rule, treatments determined to be experimental, investigational, or unproven are excluded from coverage unless an approved exception is granted following individual case review and prior plan approval by a Priority Health medical director or clinical pharmacist.

    Coding, HCPCS/CPT/ICD-10 and Regulatory Identifiers

    Breast Reconstruction Eligible HCPCS/CodesHCPCSCovered
    Q4116AlloDerm® / AlloDerm Regenerative Tissue Matrix (RTM) — Human Acellular Dermal Matrix
    Q4100Cortiva® / AlloMax® / NeoForm® — Human Acellular Dermal Matrix (or listed equivalence) / may map to C9399
    Q4122DermACELL® — Human Acellular Dermal Matrix
    Q4128FlexHD® — Human Acellular Dermal Matrix
    Q4130Strattice™ — Xenograft Acellular Dermal Matrix
    C9358SurgiMend® — Xenograft Acellular Dermal Matrix
    C9360SurgiMend® — Xenograft Acellular Dermal Matrix (alternate code)
    Burns — Eligible HCPCS/CodesHCPCSCovered
    A2043Non-living biosynthetic dressing (example BIOBRANE Dressing)
    A2044Partial-Thickness Burns / General Wound Matrix Coverage (used as grouping in document)
    C9363Integra® Meshed Bilayer Wound Matrix / Bilayer Matrix Wound Dressing
    Q4104Integra® Bilayer Matrix Wound Dressing (BMWD) / Bilayer Wound Matrix
    Q4182TransCyte™ — Human fibroblast-derived temporary skin substitute
    Burns — Additional product codesmixedCovered
    Q4105Integra® Dermal Regeneration Template (IDRT)
    C9399Coding used for various cultured epidermal/cellular skin substitutes (e.g., Epicel®, OrCel™) and other products as listed
    C8002Autologous skin cell suspension (ReCell®) — product-related code mapping
    15011Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    15012Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    15013Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    15014Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    15015Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    15016Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    15017Autologous skin cell suspension CPT/related codes (grouped 15011-15018 in document)
    1–10 of 11
    1/2
    Product HCPCS codes mentionedHCPCS
    Q4128AlloPatch Pliable, Diabetic Foot Ulcers (DFUs)
    Q4101Apligraf® (and other products listed under Q4101)
    Q4102Oasis® Wound Matrix / Oasis® Ultra Tri-Layer Matrix
    Q4124Tri-Layer Matrix
    Q4105Omnigraft Dermal Regeneration Matrix
    Q4431Dermagraft®
    Q4121Theraskin®
    Q4132Grafix®
    Q4151AmnioBand®
    Q4186EpiFix®
    1–10 of 13
    1/2
    Referenced CMS NCD/LCD identifiersmixed
    270.5Porcine Skin and Gradient Pressure Dressings (NCD reference)
    L36690LCD - Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities (reference)
    L36377LCD - Application of Skin Substitute Grafts for Treatment of DFU and VLU (reference)
    L35041LCD - Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds (reference)
    Referenced CMS NCDs/LCDsmixed
    NCD 270.5Porcine Skin and Gradient Pressure Dressings (reference to CMS NCD numbering in policy)
    LCD L36690Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremity
    LCD L36377Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower Extremities (First Coast Service Options, Inc.)
    LCD L35041Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds (Novitas Solutions, Inc.)
    Regulatory device identifiers mentionedmixed
    K130817Strattice (510(k) number) listed under breast reconstruction
    K071807SurgiMend (510(k) number)
    K140533Galaflex (510(k) number)
    K161092GalaShape 3D (510(k) number)
    K162922Galaform 3D (510(k) number)
    K896110BIOBRANEII (510(k)/PMA details)
    K242146BIOBRANE Temporary Wound Dressing and Glove
    P010016OrCel™ (PMA/HDE reference)
    P900033Integra® Dermal Regeneration (PMA)
    K021792Integra Bilayer Matrix Wound Dressing (510(k))
    1–10 of 14
    1/2
    FDA product/clearance identifiers mentionedmixed
    P950032AFDA product identifier referenced for Epifix / Apligraf/Graftskin in ulcers/diabetic foot ulcers listings
    K061711FDA/510(k) or device identifier referenced for products in the list (e.g., Epifix referenced)
    P000036AFDA product identifier referenced for Dermagraft or related products
    P900033FDA product identifier referenced for Integra Omnigraft Dermal / Regeneration Matrix
    s042Suffix or combined identifier shown as P900033/s042 in document
    BP170122Reference code appearing alongside diabetic foot ulcer entries
    K153690K-number referenced in the regulatory listings
    K102002K-number referenced in the regulatory listings
    FDA device identifiers citedmixed
    P950032AApligraf/Graftskin (listed)
    K061711Oasis Wound Matrix (listed)
    P000036ADermagraft (listed)
    P900033Integra Dermal Regeneration/Omnigraft (listed)
    P900033/s042Integra Dermal Regeneration Matrix (listed)
    K153690Primatrix (listed)
    K102002Talymed (listed)
    K112409Matristem Wound Matrix (listed)
    K172399Additional 510(k) referenced (listed)
    K132343Additional 510(k) referenced (listed)
    FDA/Regulatory product identifiers listedmixed
    P950032AApligraf/Graftskin
    K061711Oasis® Wound Matrix and Oasis Ultra Tri-Layer Matrix
    P000036ADermagraft
    P900033/s042Integra Omnigraft Dermal Regeneration Matrix
    P900033Integra Dermal Regeneration Matrix
    K153690Primatrix
    K102002Talymed
    K112409Matristem Wound Matrix
    K172399Matristem MicroMatrix
    K132343Kerecis™ Omega3 Wound (formerly MeriGen)
    1–10 of 12
    1/2
    Regulatory identifiers (P/PMA and K/510(k) numbers, HCT/P)mixed
    P900033/s042Integra Omnigraft Dermal Regeneration Matrix
    P900033Integra Dermal Regeneration Matrix
    P000036ADermagraft
    P950032AApligraf/Graftskin
    K061711Oasis Wound Matrix and Oasis Ultra Tri-Layer Matrix
    K153690Primatrix
    K102002Talymed
    K112409Matristem Wound Matrix
    K172399Matristem MicroMatrix
    K132343Kerecis™ Omega3 Wound (formerly known as MeriGen)
    1–10 of 14
    1/2
    FDA 510(k) and PMA identifiers listedmixed
    K112409Matristem Wound Matrix
    K172399Matristem MicroMatrix
    K132343Kerecis Omega3 Wound (formerly MeriGen)
    K190528Kerecis Limited MariGen Wound Extra / Marigen Wound Extra
    K213231Kerecis Silicone (Kerecis Limited)
    K241080Kerecis Parvus
    K061711Oasis Wound Matrix and Oasis Ultra Tri-Layer Matrix
    P000036ADermagraft
    P900033/s042Integra Omnigraft Dermal Regeneration Matrix
    P900033Integra Dermal Regeneration Matrix
    1–10 of 15
    1/2
    Regulatory device/product identifiers (FDA K/P numbers) referencedmixed
    K132343Kerecis Limited MariGen Wound Extra
    K190528Kerecis Silicone (Kerecis Limited)
    K213231Kerecis Parvus
    K241080Marigen Wound Extra
    K161067Mirragen™ Advanced Wound Matrix (listed)
    P000036ADermagraft (Dermagraft entries)
    P900033Integra Omnigraft Dermal Regeneration Matrix / Integra Dermal Regeneration Matrix
    P900033/s042Integra Omnigraft Dermal Regeneration Matrix (supplement)
    P950032AApligraf/Graftskin
    P950032/S016Apligraf/Graftskin (supplement)
    1–10 of 15
    1/2
    HCT/P productsmixed
    EpifixEpifix (HCT/P) — listed as HCT/P product
    ICD-10 Codes that may support medical necessityICD-10
    C50.011 - C50.929Malignant neoplasm of female breast
    C79.81Secondary malignant neoplasm of breast
    D05.00 - D05.92Carcinoma in situ of breast
    D48.60 - D48.62Neoplasm of uncertain behavior of breast
    D49.3Neoplasm of unspecified behavior of breast
    T85.44xA - T85.44xSCapsular contracture of breast implant
    N65.0Deformity of reconstructed breast
    N65.1Disproportion of reconstructed breast
    Z85.3Personal history of malignant neoplasm of breast
    Z42.8Encounter for other plastic and reconstructive surgery following medical procedure or healed injury
    1–10 of 26
    1/3
    Secondary diagnosesICD-10
    E08.40 - E08.610Diabetes mellitus due to underlying condition with diabetic neuropathy
    E09.40 - E09.610Drug or chemical induced diabetes mellitus with neurological complications
    E10.40 - E10.69Type 1 diabetes mellitus with neurological complications
    E11.40 - E11.69Type 2 diabetes mellitus with neurological complications
    E13.40 - E13.69Other specified diabetes mellitus with neurological complications
    CPT/HCPCS Codesmixed
    15011Harvest of skin for skin cell suspension autograft; first 25 sq cm or less
    15012Harvest of skin for skin cell suspension autograft; each additional 25 sq cm or part thereof
    15013Preparation of skin cell suspension autograft; first 25 sq cm or less of harvested skin
    15014Preparation of skin cell suspension autograft; each additional 25 sq cm of harvested skin
    15015Application of skin cell suspension autograft to wound and donor sites; first 480 sq cm or less
    15016Application of skin cell suspension autograft; each additional 480 sq cm or part thereof
    15017Application of skin cell suspension autograft to specialized sites; first 480 sq cm or less
    15018Application of skin cell suspension autograft to specialized sites; each additional 480 sq cm or part thereof
    C8002Processing and device components (automated skin cell suspension processing) - descriptor present
    15271Application of skin substitute graft to trunk, arms, legs; total wound surface area up to 100 sq cm; first 25 sq cm or less
    1–10 of 22
    1/3
    HCPCS product codes (medically necessary products listed)HCPCSCovered
    A2043Biobrane, per square centimeter
    A2044Biobrane glove, each
    C9358Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
    C9360Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
    C9363Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm
    Q4100Cortiva® (formerly AlloMax®, NeoForm®); DermaMatrix®; Skin substitute NOS (add-on guidance)
    Q4101Apligraf, per sq cm
    Q4102Oasis wound matrix, per sq cm
    Q4104Integra bilayer matrix wound dressing (BMWD), per sq cm (add-on)
    Q4105Integra dermal regeneration template (DRT) or Integra Omnigraft dermal regeneration matrix, per sq cm
    1–10 of 14
    1/2
    Listed HCPCS/CPT Codes (selected from this segment)HCPCS
    A2043Biobrane, per square centimeter
    A2044Biobrane glove, each
    C9358Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
    C9360Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
    C9363Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm
    Q4100Cortiva® (formerly AlloMax®, NeoForm®); DermaMatrix®
    Q4101Apligraf, per sq cm
    Q4102Oasis wound matrix, per sq cm
    Q4104Integra bilayer matrix wound dressing (BMWD), per sq cm
    Q4105Integra dermal regeneration template (DRT), per sq cm
    1–10 of 14
    1/2
    Not Separately Payable / Add-on HCPCS Codes (products listed as not separately payable or add-on in this segment)HCPCSNot Covered
    A2001InnovaMatrix AC (per sq cm) - Not separately payable (add-on; reported with primary procedure)
    A2002Mirragen Advanced Wound Matrix (per sq cm) - Not separately payable (add-on)
    A2004XcelliStem (1 mg) - Not separately payable
    A2013InnovaMatrix FS (per sq cm) - Not separately payable (add-on)
    A2014Omeza Collagen Matrix (per 100 mg) - Not separately payable
    A2016Permeaderm-B (per sq cm) - Not separately payable (add-on)
    A2017Permeaderm Glove (each) - Not separately payable (add-on)
    A2018Permeaderm-C (per sq cm) - Not separately payable (add-on)
    A2019Kerecis Omega3 MariGen Shield (per sq cm) - Not separately payable (add-on)
    A2020AC5 Advanced Wound System (AC5) NeoMatriX® (per sq cm) - Not separately payable (add-on)
    1–10 of 72
    1/8
    Excluded / Add-on Q-codesHCPCSNot Covered
    Q4168AmnioBand® Add-on; listed in addition to primary procedure
    Q4169Artacent® Wound Add-on; listed in addition to primary procedure
    Q4170Cygnus® Add-on; listed in addition to primary procedure
    Q4171Interfyl® Add-on; listed in addition to primary procedure
    Q4173PalinGen® Add-on; listed in addition to primary procedure
    Q4174PalinGen® ProMatrX® Add-on; listed in addition to primary procedure
    Q4175Miroderm® Add-on; listed in addition to primary procedure
    Q4177FlowerAmnioFlo® Add-on; listed in addition to primary
    Q4178FlowerAmnioPatch® Add-on; listed in addition to primary
    Q4179FlowerDerm® Add-on; listed in addition to primary
    1–10 of 128
    1/13
    Excluded/Add-on/Not separately payable Q-codesHCPCSNot Covered
    Q4309Procenta (per 100 mg) injectable / particulate form
    Q4310Acesso (per sq cm) Add-on; listed in addition to primary procedure
    Q4311Acesso AC (per sq cm) Add-on
    Q4312DermaBind FM (per sq cm) Add-on
    Q4313Reeva FT (per sq cm) Add-on
    Q4319SanoGraft (per sq cm) Add-on
    Q4320PelloGraft (per sq cm) Add-on
    Q4321RenoGraft (per sq cm) Add-on
    Q4322CaregraFT (per sq cm) Add-on
    Q4323alloPLY (per sq cm) Add-on
    1–10 of 108
    1/11
    Collagen, nerve, and scaffold C-codes — Not Separately PayableHCPCSNot Covered
    C9352Microporous collagen implantable tube (NeuraGen® Nerve Guide), Per centimeter length — Not separately payable
    C9353Microporous collagen implantable slit tube (NeuraWrap® Nerve Protector), Per centimeter length — Not separately payable
    C9354Acellular pericardial tissue matrix of nonhuman origin (Veritas®), Per square centimeter — Not separately payable
    C9355Collagen nerve cuff (NeuroMatrix®), Per 0.5 centimeter length — Not separately payable
    C9356Tendon porous matrix of cross-linked collagen and glycosaminoglycan (TenoGlide® Tendon Protector Sheet), Per square centimeter — Not separately payable
    C9359Porous purified collagen matrix bone void filler (Integra® Mozaik Osteoconductive Scaffold Putty), Per 0.5 cc — Not separately payable
    C9361Collagen matrix nerve wrap (NeuroMend® Collagen Nerve Wrap), Per 0.5-centimeter length — Not separately payable
    C9362Porous purified collagen matrix bone void filler (Integra® Mozaik Osteoconductive Scaffold Strip), Per 0.5 cc — Not separately payable
    C9364Porcine implant (Permacol®), per sq cm — Not separately payable
    Referenced FDA PMA / 510(k) identifiersmixed
    P900033INTEGRA® Dermal Regeneration Template - PMA identifier (FDA PMA P900033)
    P010016AORCEL® bilayered cellular matrix - PMA identifier (FDA PMA P010016A)
    P960007TransCyte™ temporary wound covering - PMA identifier (FDA PMA P960007)
    K061711Oasis® Wound Matrix - 510(k) summary (K061711)
    K083898SurgiMend® Collagen Matrix - 510(k) (referenced earlier in document portion)
    Burn TBSA — clinical threshold
    Burn TBSA threshold≥30% total body surface area (TBSA) for extensive deep dermal or full‑thickness burns
    Indication contextUse when dermal or epidermal replacement is clinically indicated (e.g., donor site limitation, medically unstable patient, critical anatomic area)
    Adjunctive requirementProducts used as temporary coverage, dermal regeneration templates, or adjuncts to autografting when autograft not feasible
    Chronic ulcer healing response & perfusion thresholds
    Chronic ulcer early healing thresholdFailure to demonstrate meaningful healing defined as ≥50% wound area reduction after ≥4 weeks of documented adherence to standard wound/ulcer care
    Standard care components requiredRegular debridement when indicated; appropriate dressings/cleansing; infection assessment/management; etiology‑specific therapy (DFU offloading; VLU sustained compression)
    Perfusion requirementAdequate arterial perfusion documented by palpable pedal pulses or Doppler, or ABI ≥0.70 and ≤1.30; if ABI unreliable (>1.30), toe pressure ≥30 mmHg or acceptable TBI
    VLU trial durationAdequate trial for VLUs commonly ≥4–6 weeks before adjunctive therapy considered
    DFU-specific thresholds & documentation
    DFU glycemic thresholdHemoglobin A1c assessed within prior 90 days; HbA1c <12% required unless clinical documentation justifies proceeding
    DFU documentation requirementsDocument diabetes type, evidence of optimized diabetes management, and offloading as part of standard care prior to skin substitute use
    DFU perfusion/assessmentObjective vascular assessment (palpable pulses/Doppler, ABI, or toe pressure/TBI when ABI unreliable) is required before adjunctive skin substitute use

    Prior Authorization, Documentation, Billing and Denial Risk

    Prior Authorization

    Prior authorization required for listed product codes

    Obtain prior authorization per payer process for the specific HCPCS/CPT/product codes listed in the policy before billing; inclusion of a product in coding tables does not itself establish medical necessity.

    • Examples of listed codes include Q4116, Q4100, Q4122, Q4128, Q4130, C9358, C9360 and CPT codes 15011–15018.
    Prior Authorization

    Prior authorization and code-based utilization limits

    When product-specific HCPCS codes are used, obtain prior authorization consistent with the utilization limits in each product section (initial application limits and maximum total applications within a 12‑week episode).

    • Example limits: AlloPatch (Q4128) — initial ≤5 applications; up to 8 applications per ulcer within 12 weeks. Dermagraft (Q4431) — initial ≤5; up to 8 in 12 weeks. Many products: initial 1 and up to 4–5 applications in 12 weeks depending on product.
    • Applications beyond 12 weeks per ulcer are not medically necessary.
    Prior Authorization

    Prior authorization may be required per CMS/LCD

    Confirm whether CMS NCDs/LCDs or local coverage articles apply and obtain prior authorization when required by those determinations or by the member's plan.

    • MAC/LCD/NCD guidance takes precedence; check the Medicare Coverage Database and the member's plan documents.
    Prior Authorization

    Prior authorization for adjunctive skin substitute use

    Obtain prior authorization for adjunctive skin substitute use when the policy requires the product to be used only after failure of optimized standard care and when product-specific indications include adjunctive use.

    • Document prior conservative management (debridement, dressings, infection control, offloading for DFU or compression for VLU) when submitting the authorization request.
    Documentation Required

    Include FDA product/clearance identifiers in PA submissions

    Reference the FDA product/clearance identifiers and device names listed in the regulatory sections when submitting prior authorization or coverage review documentation for a specific product.

    • Examples of FDA identifiers in the policy: P950032A, K061711, P000036A, P900033/s042, BP170122.
    Documentation Required

    FDA device identifiers for PA verification

    Use the FDA PMA/510(k)/HCT/P numbers provided in the policy to help verify product regulatory status during prior authorization review.

    • Cite identifiers such as P950032A (Apligraf), K061711 (Oasis), P000036A (Dermagraft), and P900033 variants when relevant.
    Note

    Regulatory listings do not by themselves require PA

    This regulatory listing section enumerates FDA identifiers for products and does not impose additional prior authorization requirements by itself.

    • Regulatory listings are informational; prior authorization requirements are described elsewhere in the policy or by the payer.
    Note

    No PA rule stated in regulatory listing

    The regulatory identifier tables provide FDA clearance/approval numbers and product names but do not specify prior authorization rules; use them for verification only.

    • Providers should not assume authorization requirements from these listings alone.
    Note

    FDA clearance references (informational)

    FDA clearance references and identifiers are listed for provider reference; they support verification during utilization review but do not establish prior authorization criteria.

    • Documented examples include K112409, K172399, and K132343 among others.
    Note

    Regulatory listing — PA not specified here

    Regulatory product identifiers are listed for reference; the policy's regulatory listings do not themselves mandate prior authorization.

    • Use these identifiers when validating product clearance during PA or claims review.
    Prior Authorization

    Prior authorization and correct billing for application/product

    Obtain any required prior authorization before billing skin substitute application and related product codes; ensure the application code and product code are billed together on the same claim for the same date of service.

    • Application codes (e.g., 15271–15278, G0681–G0684) must be billed on same claim with product HCPCS/CPT codes.
    • Follow payer prior authorization process when required.
    Billing Rule

    Report exact product HCPCS/CPT and follow add-on instructions

    Bill the exact HCPCS/CPT product code(s) that correspond to the product used and follow add-on/list-separately instructions where noted in the coding section.

    • Many product HCPCS (Q-codes) are designated add-on and must be listed separately in addition to the primary procedure.
    Billing Rule

    Use mapped Q-code for add-on/excluded products

    When a product is designated as an add-on or excluded item in the policy, bill the mapped Q-code and list it in addition to the primary procedure; do not bill it as a standalone primary procedure.

    • Examples of add-on Q-codes are Q4168 through Q4326; follow the policy mapping when billing.
    Prior Authorization

    PA may be required — submit medical necessity documentation

    Prior authorization may be required for certain products or procedures; when required, submit documentation demonstrating medical necessity and follow the plan's prior authorization process.

    • Individual case review with prior plan approval is required for investigational or unproven treatments.
    Prior Authorization

    When PA is required, obtain plan approval with supporting documentation

    If prior authorization is required, providers must submit requests showing medical necessity and obtain plan approval; individual case review may allow coverage for investigational treatments with prior approval.

    • Decisions for investigational treatments are made by a Priority Health medical director or clinical pharmacist.
    Step Therapy

    Document ≥4 weeks failed standard care (≥50% area reduction threshold)

    Document and demonstrate failure of an adequate trial of standard wound care (e.g., wound failed to show ≥50% area reduction after ≥4 weeks of documented standard care) before requesting advanced skin substitute therapy.

    • Standard care components include debridement when indicated, appropriate dressings, infection assessment/management, and etiology-specific measures (offloading for DFU; compression for VLU).
    Step Therapy

    Adjunctive use only — document standard care and rationale

    Use skin substitutes only as adjuncts after an adequate trial of standard wound care (debridement, dressings, infection control, and etiology-specific therapy) and document the rationale for adjunctive product selection.

    • Adjunctive use must not replace foundational therapy (e.g., offloading or sustained compression).
    Step Therapy

    Stepwise escalation — optimize foundational care before advanced products

    Follow a stepwise escalation strategy: optimize etiology-specific standard care (e.g., compression for VLUs; offloading for DFUs) and escalate to product-specific adjunctive therapies only when wounds fail to progress.

    • Consider RCT-proven advanced agents for chronic DFUs that fail to heal with optimal standard care.
    Step Therapy

    Maintain optimized etiology-specific standard care before application

    Optimize and continue etiology-specific standard care (compression for VLUs; offloading and diabetes management for DFUs) before and during adjunctive skin substitute therapy.

    • For DFU, ensure offloading is maintained and HbA1c assessment and diabetes optimization are documented.
    Note

    Regulatory listing — no step therapy rules here

    This regulatory listing chunk is informational and does not impose step therapy or authorization actions; consult the clinical criteria sections for required prerequisites.

    • Regulatory identifiers here are for provider reference only.
    Note

    Regulatory listings — no PA or step therapy specified

    Regulatory identifier listings in this section are informational; they do not specify provider actions or authorization steps.

    • Use identifiers for verification, but follow clinical criteria elsewhere in the policy.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Check plan-level requirements and member benefits

    Plan- or group-specific documents may impose additional utilization rules; verify member-specific benefits and any state-mandated provisions before requesting authorization or billing.

    • For self-funded (ASO) and individual plans consult the plan document; Medicare coverage is determined by CMS when an NCD/LCD applies.
    Documentation Required

    Document wound assessment, infection control, and treatment plan

    Include the following clinical details in prior authorization and chart documentation: wound depth, total body surface area (when relevant), anatomic location, functional risk areas, wound bed status and infection control, and a treatment plan explaining why standard therapy alone is insufficient.

    • For burns include TBSA, burn depth, and donor-site considerations; for ulcers include serial wound measurements and healing trajectory.
    Documentation Required

    DFU-specific documentation: diabetes status, HbA1c, offloading

    For DFU prior authorizations and charting, document diabetes type, recent HbA1c (within 90 days), evidence that diabetes management is being optimized, and that effective offloading is in place.

    • Policy requires HbA1c <12% within 90 days unless documentation justifies proceeding despite higher values.
    Documentation Required

    Document wound depth, no exposed deep structures, and ≥4 weeks SOC adherence

    Before application, document wound depth (partial/full-thickness), absence of exposed bone/tendon/muscle/joint capsule, adherence to ≥4 weeks of standard wound care, and objective perfusion assessment as applicable (palpable pulses, ABI, toe pressure/TBI).

    • Record serial wound measurements and percent area change to support failure of standard care (e.g., <50% reduction after ≥4 weeks).
    Documentation Required

    Document optimized standard care and vascular assessment

    Document that standard wound care was optimized (debridement when indicated, infection assessment/management, moisture balance) and include objective vascular assessment (ABI, toe pressure, or TBI) and wound healing trajectory in the record.

    • Include notes on offloading for DFU or sustained compression for VLU and serial percent area changes after 4 weeks.
    Documentation Required

    Document diagnosis, duration, response to SOC, and product rationale

    Confirm and document the diagnosis (e.g., VLU with venous disease evaluation and exclusion/assessment of arterial disease), duration and response to an adequate trial of standard care, wound measurements/serial progress, and rationale for the chosen adjunctive product when submitting prior authorization.

    • For VLU include documentation of sustained compression therapy and venous evaluation.
    Documentation Required

    Reference FDA identifiers for coverage and claims validation

    Consult the regulatory identifier tables for FDA product identifiers when validating product regulatory status for coverage or claims submission; include matching product identifiers when available.

    • Examples: P950032A (Apligraf), K061711 (Oasis), P000036A (Dermagraft).
    Documentation Required

    Document product name and FDA 510(k)/PMA identifier

    Document the exact product name and corresponding FDA 510(k) or PMA identifier (when applicable) in the prior authorization and claims submission to support verification.

    • Policy examples: Oasis K061711; Dermagraft P000036A; Apligraf P950032A.
    Note
    Note
    Note
    Note
    Billing Rule

    Include supporting ICD-10 diagnosis codes

    Use the listed ICD-10 diagnosis codes to support medical necessity on authorization requests and claims when applicable to the clinical indication.

    • Examples include L97.x for non-pressure chronic ulcers, I83.x for venous ulcers, and diabetes codes E10–E13 with complications.
    Billing Rule

    Provide explanatory notes for unlisted/NOS skin substitute codes

    When billing with an unlisted or 'NOS' skin substitute code (e.g., Q4100 or other unlisted device codes), include an explanatory note describing the product, reason for use, and relation to the primary procedure.

    • Unlisted device lines should be accompanied by clinical rationale and product details to support medical necessity and coding.
    Billing Rule

    Bill using policy mapping; adhere to add-on Q-code designations

    Follow the policy's billing designations and Q-code mapping when submitting claims; many named products are designated 'Add-on; listed in addition to primary procedure' and must be billed accordingly.

    • Failure to bill add-on items as specified may trigger claim review or denial.
    Prior Authorization

    Submit medical necessity evidence with PA; investigational treatments need prior approval

    When prior authorization is required, submit documentation that demonstrates medical necessity; individual case review may allow coverage for investigational treatments only with prior plan approval.

    • Exceptions for investigational treatments require review by a Priority Health medical director or clinical pharmacist and prior plan approval.
    Note
    Denial Risk

    Denial risk: missing wound documentation

    Failure to document wound characteristics, adherence to standard care, and a treatment plan prior to application may result in denial of coverage.

    • Documentation prerequisite explicitly required by the policy (wound characteristics and treatment plan present prior to application).
    Denial Risk

    Denial risk: inadequate trial of standard care

    If an adequate trial of standard wound care (commonly ≥4 weeks; ≥4–6 weeks for VLUs) is not documented, the request may be denied for failure to meet policy prerequisites.

    • Policy cites failure to demonstrate ≥50% area reduction after ≥4 weeks as a common clinical decision point for escalation.
    Denial Risk

    Denial triggers: applications >12 weeks or >10 total in 12 weeks

    Treatments beyond 12 weeks per ulcer or more than ten total applications per ulcer within a 12‑week episode are considered not medically necessary and may be denied.

    • Multiple different substitutes concurrently or sequentially for the same ulcer without documented rationale is also not medically necessary.
    Note

    CMS/LCD precedence may affect authorization and coverage

    Coverage may be governed by applicable federal/state mandates and CMS NCD/LCD determinations; failure to follow those mandates or local coverage rules can trigger denials.

    • Refer to the Medicare Coverage Database for current NCD/LCD/LCA guidance.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Denial Risk

    Claim denial risk: application and product codes must be billed together

    Failure to bill the appropriate skin substitute application code together with the product code on the same claim for the same date of service may result in claim denial.

    • Ensure application CPT/HCPCS (e.g., 15271–15278, G0681–G0684) and product HCPCS/Q-code are on the same claim and date of service.
    Denial Risk

    Denial risk: non‑medically necessary items per policy

    Claims for products that do not meet the policy's medical necessity criteria (including excluded, investigational, or unproven items) are not eligible for coverage and may be denied.

    • Examples include prophylactic use on closed ulcers, infected/ischemic wounds not adequately treated, and routine cosmetic uses outside criteria.
    Denial Risk

    Denial risk: exclusions and add-on billing must be followed

    Products listed as add-on or not separately payable must be billed as add-on items (in addition to the primary procedure); incorrect submission or billing as standalone may result in denial.

    • Large lists of Q-codes are designated as add-on/not separately payable; review the coding section and bill accordingly.
    Denial Risk

    Denial risk for excluded Q/HCPCS codes billed incorrectly

    Claim lines using Q-codes or HCPCS codes designated as add-on or not separately payable may be denied if billed incorrectly or outside the policy rules.

    • Verify mapping and add-on designation before submitting claims to avoid denials.
    Denial Risk

    Denial risk: investigational/experimental treatments require prior approval

    Coverage determinations for investigational, experimental, or unproven treatments require individual case review and prior plan approval; absent approved exception, such treatments are generally excluded from coverage.

    • Allowed exceptions are limited (e.g., terminal illness or chronic, deteriorating severe disease) and require review by a medical director or clinical pharmacist.

    Background and Rationale

    Skin substitutes and acellular dermal matrices are used as adjuncts to provide temporary or definitive wound coverage, to supply a scaffold that supports revascularization and granulation, and to reduce fluid loss or contamination risk. Because composition and intended use vary, clinical outcomes and risks are interpreted on a product‑ and indication‑specific basis, and the strongest evidence may be limited to selected products and settings.

    Definitions and Terms

    FDA-regulated product — Products regulated by the FDA (PMA, 510(k), HDE, or HCT/P) used consistent with their regulatory status
    Regulatory scopeProducts regulated by the FDA (PMA, 510(k), HDE, or HCT/P) must be used consistent with their regulatory status
    Documentation implicationProduct regulatory identifier (510(k)/PMA/HCT/P) and exact product name should be documented in prior authorization and claims when applicable
    Exception pathwayInvestigational or unproven treatments may be considered only via individual case review with prior plan approval
    Acellular Dermal Matrix (ADM) — Biologic soft-tissue reinforcement used adjunctively in implant-based breast reconstruction
    DefinitionAcellular dermal matrix (ADM) is a biologic soft-tissue reinforcement used adjunctively in implant-based breast reconstruction—not intended as a standalone reconstructive material
    Clinical roleUsed to provide soft-tissue support, improve pocket control, or reinforce thin/compromised flaps in implant-based reconstruction
    Coverage noteADM is considered medically necessary only as adjunctive support when specified reconstructive criteria are met
    Standard wound/ulcer care — Includes debridement, dressings, infection assessment/management, compression/offloading
    ComponentsStandard wound/ulcer care includes regular debridement when indicated, appropriate dressings and wound cleansing, infection assessment/management, and etiology-specific foundational therapy (offloading for DFU; sustained compression for VLU)
    PurposeOptimize wound bed and address underlying etiology before escalation to adjunctive skin substitutes
    DocumentationProviders must document adherence to these components during the ≥4-week trial prior to adjunctive therapy
    Meaningful healing — At least a 50% reduction in ulcer area after ≥4 weeks of documented adherence to standard wound care
    Meaningful healing thresholdAt least a 50% reduction in ulcer area after ≥4 weeks of documented adherence to standard wound care
    UseDefines failure of standard care and the decision point for considering adjunctive skin substitute therapies
    Required evidenceSerial wound measurements documenting percent area change over the 4-week trial
    Autologous skin cell suspension (ASCS) / ReCell — Point-of-care device-generated suspension of non-cultured autologous skin cells
    DefinitionAutologous skin cell suspension (ASCS / ReCell) is a point-of-care device-generated suspension of non-cultured autologous skin cells applied to wounds to promote epithelial regeneration and reduce donor-site requirements
    Clinical evidenceRCTs in burns show donor-skin sparing benefits; evidence in DFU is mixed and product-specific
    Coding noteAssociated CPT codes 15011–15018 describe harvest, preparation, and application steps and surface-area thresholds
    Dystrophic Epidermolysis Bullosa (DEB) — Rare inherited skin-fragility disorder due to COL7A1 variants
    DefinitionDystrophic epidermolysis bullosa (DEB) is a rare inherited skin-fragility disorder due to COL7A1 pathogenic variants causing defective type VII collagen and fragile dermal-epidermal adhesion
    Clinical featuresRecurrent blistering, chronic wounds, scar formation, risk of mitten-hand deformities and aggressive cutaneous squamous cell carcinoma
    ManagementSupportive multidisciplinary care; advanced coverings may be used selectively to reduce shear and repetitive injury
    Venous Leg Ulcer (VLU) — Chronic open skin lesion of the lower extremity occurring with chronic venous disease
    DefinitionVenous leg ulcer (VLU) is a chronic open skin lesion of the lower extremity occurring with chronic venous disease and ambulatory venous hypertension
    Management emphasisSustained therapeutic compression is first-line therapy and must be continued when using adjunctive skin substitutes
    Trial durationConsider adjunctive therapies only after an adequate trial of standard VLU care (commonly ≥4–6 weeks)
    Epifix (HCT/P) — An HCT/P referenced by identifier P950032A
    Example productEpifix is listed as an HCT/P product and referenced by FDA identifier P950032A in regulatory listings
    Regulatory roleHCT/P designation indicates human cells/tissues subject to specific regulatory considerations
    Provider actionReference the listed FDA identifier when validating product regulatory status in prior authorization or claims
    Apligraf/Graftskin — A skin substitute product referenced with identifier P950032A
    ExampleApligraf/Graftskin is a named skin substitute product referenced with regulatory identifier(s) in the policy (e.g., P950032A)
    Clinical useIncluded in regulatory listings for DFU and other ulcer indications; medical necessity determined by meeting clinical criteria
    DocumentationProviders should include exact product name and corresponding FDA identifier in requests when applicable
    FDA product/clearance identifiers — Alphanumeric codes referencing FDA premarket approvals (P), 510(k) clearances (K), or HCT/P designations
    DefinitionFDA product/clearance identifiers are alphanumeric codes (e.g., P950032A, K061711, K153690) referencing PMA, 510(k), or HCT/P regulatory statuses
    PurposeUsed for device/product verification and may be referenced in prior authorization or claims documentation
    Provider tipInclude the FDA identifier and product name when submitting prior authorization requests to aid verification
    FDA identifier codes — Examples of numeric/alphanumeric FDA identifiers listed in the document
    ExamplesProduct identifiers listed include P950032A, K061711, P000036A, P900033/s042, K153690, K102002, K112409, K172399, K132343, K190528
    UseThese identifiers map products to regulatory records and support coverage/claim validation
    NoteRegulatory listings do not themselves establish medical necessity; clinical criteria must be met
    HCT/P — Human cells, tissues, and cellular and tissue-based products (noted for Epifix)
    DefinitionHCT/P denotes human cells, tissues, and cellular and tissue-based products and is applied to certain listed products (e.g., Epifix)
    ImplicationHCT/P products are regulated under specific FDA criteria and must be used consistent with that regulatory status
    DocumentationProviders should note HCT/P designation in prior authorization and claims when applicable
    Skin cell suspension autograft (RECELL example) — Codes 15011-15018 describe harvest, preparation, and application
    RECELL codingCPT codes 15011–15018 describe harvest, preparation, and application of skin cell suspension autografts (e.g., ReCell) with surface-area-based increments
    ScopeCodes cover harvesting (first 25 sq cm and additional increments), preparation, and application (first 480 sq cm and additional increments)
    Billing noteBill the specific CPT(s) corresponding to harvest/preparation/application and list separately as appropriate
    Skin substitute application codes — Codes 15271-15278 and G0681-G0684 represent application segmented by wound surface area
    Application codesSkin substitute application codes (15271–15278 and G0681–G0684) segment application by wound surface area and anatomic site
    IncrementsDescriptors include first 25 sq cm, each additional 25 sq cm, 100 sq cm blocks, and 1% body area for infants/children as specified
    Billing requirementUse the appropriate application code(s) matching wound area and site; list separately in addition to the primary procedure when required
    Not Medically Necessary — Procedures, services, or products that do not meet the medical necessity criteria
    DefinitionNot Medically Necessary: procedures, services, or products that do not meet the medical necessity criteria in this policy are not eligible for coverage
    ImplicationItems lacking sufficient evidence or used outside specified indications are excluded
    ProcessDenials may be issued for nonconforming uses; individual case review may be available for investigational therapies with prior approval
    Not Separately Payable — Items considered integral to another procedure or lacking evidence to warrant separate payment
    DefinitionNot Separately Payable: items integral to another procedure or lacking evidence for independent payment are designated not separately payable/add-on
    ExamplesExtensive lists of A20xx and Q4xxx codes and specific C-codes are mapped as add-on/not separately payable in the policy
    Billing actionWhen a product is listed as add-on/not separately payable, bill per policy mapping and include the primary procedure as required
    Add-on; listed in addition to primary procedure — Product is billed in addition to a primary procedure
    DefinitionAdd-on designation: product is billed in addition to a primary procedure using a specified Q-code rather than as a standalone primary procedure
    Billing implicationProviders must reference the mapped Q-code and ensure primary procedure billing when submitting claims for add-on products
    ExamplesMultiple Q4xxx codes (Q4168–Q4326) are mapped as add-on items in the exclusions section
    Injectable / flowable / particulate form — Formulation of the product (may carry different billing designation)
    Formulation noteInjectable, flowable, or particulate product formulations are explicitly noted and may carry different billing designations (often add-on Q-codes)
    Billing exampleSome injectable/flowable products are listed with per-0.5 cc or per-mg descriptors and mapped to specific Q-codes (see policy lists)
    Provider actionConfirm the product form and map to the correct Q/HCPCS code before billing (explanatory notes required for unlisted devices)
    Individual case review — Coverage for investigational treatments may be granted with prior plan approval
    Review optionIndividual case review may allow coverage for investigational or unproven treatments with prior plan approval
    Decision authorityAll determinations for experimental/investigational treatments are made by a Priority Health medical director or clinical pharmacist
    Exception criteriaExceptions considered when condition is terminal or a chronic, life‑threatening, severely disabling disease causing serious clinical deterioration
    Skin substitute / dermal matrix — Products including acellular dermal matrices, bilayered cellular matrices, placental membranes, and other scaffolds
    ScopeSkin substitutes and dermal matrices include acellular dermal matrices, bilayered cellular matrices, placental membranes, and other biologic or synthetic scaffolds used to promote wound healing or soft-tissue reconstruction
    Clinical roleUsed as adjuncts to optimized standard care for chronic ulcers, burns, or where autografting is limited
    Evidence considerationEffectiveness and safety are product- and indication-specific; high-quality RCT evidence is required for supportive coverage